Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For InjectionBusiness Wire • 10/20/20
Xeris Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceBusiness Wire • 09/08/20
Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating OfficerBusiness Wire • 08/20/20
Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?Zacks Investment Research • 08/18/20
Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in SessionZacks Investment Research • 08/11/20
Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/20
Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate HighlightsBusiness Wire • 08/10/20
Xeris Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020Business Wire • 08/03/20
Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path ForwardBusiness Wire • 07/30/20
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/28/20
Xeris Pharmaceuticals Announces Full Exercise of Underwriters’ Options to Purchase Additional Shares and Additional NotesBusiness Wire • 07/15/20
Xeris Pharmaceuticals Announces Gvoke HypoPen™ – the First Autoinjector for Severe Hypoglycemia – Now AvailableBusiness Wire • 07/01/20
Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025Business Wire • 06/26/20
Xeris Pharmaceuticals Announces Proposed Public Offerings of $20 Million of Common Stock and $60 Million of Convertible Senior NotesBusiness Wire • 06/24/20
Xeris Pharmaceuticals' (XERS) CEO Paul Edick on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/09/20
Xeris Pharmaceuticals Inc (XERS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/20
Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/11/20
Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/11/20
Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 03/04/20
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common StockGlobeNewsWire • 02/12/20